662
Participants
Start Date
October 29, 2018
Primary Completion Date
April 25, 2019
Study Completion Date
April 26, 2019
Insulin degludec
Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.
Novo Nordisk Investigational Site, Calgary
Novo Nordisk Investigational Site, Edmonton
Novo Nordisk Investigational Site, Vancouver
Novo Nordisk Investigational Site, Halifax
Novo Nordisk Investigational Site, Shubenacadie
Novo Nordisk Investigational Site, Sydney
Novo Nordisk Investigational Site, Ajax
Novo Nordisk Investigational Site, Brampton
Novo Nordisk Investigational Site, Cambridge
Novo Nordisk Investigational Site, Concord
Novo Nordisk Investigational Site, Etobicoke
Novo Nordisk Investigational Site, Guelph
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, Markham
Novo Nordisk Investigational Site, Markham
Novo Nordisk Investigational Site, Nepean
Novo Nordisk Investigational Site, Oakville
Novo Nordisk Investigational Site, Orillia
Novo Nordisk Investigational Site, Scarborough Village
Novo Nordisk Investigational Site, Smiths Falls
Novo Nordisk Investigational Site, Tecumseh
Novo Nordisk Investigational Site, Toronto
Novo Nordisk Investigational Site, Toronto
Novo Nordisk Investigational Site, Gatineau
Novo Nordisk Investigational Site, Laval
Novo Nordisk Investigational Site, Montreal
Novo Nordisk Investigational Site, Montreal
Novo Nordisk Investigational Site, Montreal
Novo Nordisk Investigational Site, Montreal
Novo Nordisk Investigational Site, Pierrefonds
Novo Nordisk Investigational Site, Terrebonne
Lead Sponsor
Novo Nordisk A/S
INDUSTRY